Tag Archives: Mainz Biomed

October 2023—Mainz Biomed announced results of an independent feasibility study conducted in collaboration with members of the National Cancer Institute’s Early Detection Research Network to evaluate the company’s portfolio of five mRNA biomarkers, which it acquired from Université de Sherbrooke, Quebec.

Aug. 7, 2023—Mainz Biomed announced results of an independent feasibility study conducted in collaboration with members of the National Cancer Institute’s Early Detection Research Network to evaluate the company’s portfolio of five mRNA biomarkers, which it acquired from Université de Sherbrooke, Quebec.